ATCC used cutting-edge CRISPR/Cas9 gene-editing technology to develop STAT1 knockout or STAT1/BAX double knockout cell lines capable of producing high-titer viral stocks. Discover how these advanced biological models can be used in your vaccine and gene therapeutic development projects.

ATCC has developed titered mycoplasma reference standards for comparing PCR and culture-based detection methods, and quantitative mycoplasma DNA certified reference materials for use as external controls in inclusivity/exclusivity testing and establishing limits of detection.

When evaluating a novel viral-vector-based gene therapy, accurately determining dose and potency is essential for patient safety. ATCC supports this need by providing internationally accepted viral reference materials that enable the standardization of quantification techniques between organizations.

ATCC provides pharmaceutical testing labs with the top-quality, fully characterized strains needed to maintain the highest levels of product integrity and reputation.

In this article, we will discuss the effects of mycoplasma contamination, how this form of adulteration can affect cell-based drug development, and several quality control techniques and related products that can be used in the detection of mycoplasma contamination.

ATCC generated CAR-T Target Luciferase Reporter Cells lines that have high endogenous expression of clinically relevant cell surface tumor antigens, such as CD19, CD20, and HER2. These new immuno-oncology tools are comprised of both solid and liquid tumor cell lines that exhibit sensitive and stable luciferase reporter expression.